Contact this trialFirst, we need to learn more about you.
Retinoid X Receptor Agonist
Bexarotene + Radiotherapy for Cutaneous T-Cell Lymphoma
Recruiting1 awardPhase 1
New York, New York
This trial tests the safety of combining bexarotene, a vitamin A derivative, with TSEB radiotherapy in patients with mycosis fungoides, a type of skin lymphoma. Bexarotene helps stop and kill cancer cells, while TSEB radiotherapy uses low-dose radiation to treat the skin. Researchers believe this combination may be more effective than using each treatment separately. Bexarotene has been used for both early and advanced cutaneous T-cell lymphoma (CTCL).
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service